Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Bioorg Med Chem Lett ; 37: 127847, 2021 04 01.
Artigo em Inglês | MEDLINE | ID: mdl-33571648

RESUMO

To develop methodology to predict the potential druggability of middle molecules, we examined the structure, solubility, and permeability relationships of a diverse library (HKDL ver.1) consisting of 510 molecules (359 natural product derivatives, 76 non-natural products, 46 natural products, and 29 non-natural product derivatives). The library included peptides, depsipeptides, macrolides, and lignans, and 476 of the 510 compounds had a molecular weight in the range of 500-2000 Da. The solubility and passive diffusion velocity of the middle molecules were assessed using the parallel artificial membrane permeability assay (PAMPA). Quantitative values of solubility of 471 molecules and passive diffusion velocity of 287 molecules were obtained, and their correlations with the structural features of the molecules were examined. Based on the results, we propose a method to predict the passive diffusion characteristics of middle molecules from their three-dimensional structural features.


Assuntos
Bibliotecas de Moléculas Pequenas/química , Difusão , Membranas Artificiais , Estrutura Molecular , Permeabilidade , Solubilidade
2.
J Org Chem ; 83(15): 7672-7682, 2018 08 03.
Artigo em Inglês | MEDLINE | ID: mdl-30004223

RESUMO

Conformationally restricted analogues of SPD-304, the first small-molecule TNFα inhibitor, in which two heteroaryl groups, indole and chromone, are connected by chiral methyl- or ethyl- cis-cyclopropane, were designed. Synthesis of these molecules was achieved via Suzuki-Miyaura or Stille coupling reactions with chiral bromomethylenecyclopropane or iodovinyl- cis-cyclopropane as the substrate, both of which were prepared from chiral methylenecyclopropane as a common intermediate, constructing the heteroaryl-methyl or -ethyl- cis-cyclopropane structures as key steps. This study presents an efficient synthesis of a series of chiral cis-cyclopropane conjugates with two heteroaryl groups.


Assuntos
Cromonas/química , Ciclopropanos/síntese química , Ciclopropanos/farmacologia , Indóis/química , Fator de Necrose Tumoral alfa/antagonistas & inibidores , Técnicas de Química Sintética , Ciclopropanos/química , Desenho de Fármacos , Estereoisomerismo
3.
Sci Rep ; 13(1): 12758, 2023 08 07.
Artigo em Inglês | MEDLINE | ID: mdl-37550344

RESUMO

Aneurysmal subarachnoid hemorrhage (aSAH) is a serious condition with high mortality and a high permanent disability rate. In this study, we examined the association of clinical outcome with the Controlling Nutritional Status (CONUT) score during hospitalization in aSAH patients. A single-center, retrospective observational study was conducted at Gifu University Hospital. Patients transported to the emergency room for aSAH and diagnosed with World Federation of Neurosurgical Societies (WFNS) grade III and IV aSAH between April 2004 and March 2021 were enrolled. A logistic regression model was constructed to evaluate the association of the CONUT score with a modified Rankin scale (mRS) ≥ 3 and delayed cerebral ischemia (DCI). 127 patients diagnosed with WFNS grade III and IV aSAH were analyzed. CONUT score was significantly associated with mRS ≥ 3 during hospitalization. The score obtained by subtracting the CONUT score at admission from the maximum CONUT score was significantly associated with mRS ≥ 3 at discharge. Moreover, the score obtained by subtracting the CONUT score at admission from the maximum CONUT score during the first 14 days was significantly associated with DCI within 14 days from admission. These findings indicate that CONUT score during hospitalization may be a useful daily marker for predicting poor outcomes in aSAH patients.


Assuntos
Isquemia Encefálica , Hemorragia Subaracnóidea , Humanos , Hemorragia Subaracnóidea/complicações , Estado Nutricional , Estudos Retrospectivos , Isquemia Encefálica/complicações , Infarto Cerebral/complicações , Hospitalização
4.
Anticancer Res ; 41(3): 1615-1620, 2021 Mar.
Artigo em Inglês | MEDLINE | ID: mdl-33788757

RESUMO

BACKGROUND/AIM: We evaluated the efficacy of primary prophylaxis with pegfilgrastim (PEG) for febrile neutropenia (FN) in small cell lung cancer (SCLC) patients receiving amrubicin (AMR). PATIENTS AND METHODS: A retrospective cohort study was conducted in patients with SCLC receiving AMR as second-line therapy. RESULTS: A total of 33 patients were treated with AMR (no PEG group), while 13 patients were treated with AMR plus prophylactic administration of PEG (PEG group). The severity of neutropenia was significantly reduced in the PEG group compared to the no PEG group (p=0.02). The incidence of FN in the no PEG and PEG groups was 27.3% and 7.7%, respectively. The time to development of FN tended to be longer in the PEG group compared to the no PEG group (p=0.132). CONCLUSION: Primary prophylaxis with PEG may be beneficial in reducing the risk of FN in patients with SCLC receiving AMR.


Assuntos
Antraciclinas/efeitos adversos , Antineoplásicos/efeitos adversos , Neutropenia Febril/prevenção & controle , Filgrastim/uso terapêutico , Neoplasias Pulmonares/tratamento farmacológico , Polietilenoglicóis/uso terapêutico , Carcinoma de Pequenas Células do Pulmão/tratamento farmacológico , Idoso , Neutropenia Febril/epidemiologia , Feminino , Humanos , Neoplasias Pulmonares/mortalidade , Masculino , Estudos Retrospectivos , Carcinoma de Pequenas Células do Pulmão/mortalidade
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA